These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1610 related items for PubMed ID: 31320594

  • 1. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y.
    Clin Cancer Res; 2019 Nov 15; 25(22):6815-6826. PubMed ID: 31320594
    [Abstract] [Full Text] [Related]

  • 2. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
    Wu S, Liu F, Gai Y, Carter J, Edwards H, Hüttemann M, Wang G, Li C, Taub JW, Wang Y, Ge Y.
    Leuk Res; 2024 Sep 15; 144():107547. PubMed ID: 38968731
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
    Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, Mody V, Choo EF, Dail M, Shah NP, Konopleva M, Sampath D, Lasater EA.
    Haematologica; 2021 Apr 01; 106(4):1034-1046. PubMed ID: 32414851
    [Abstract] [Full Text] [Related]

  • 7. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
    Garitano-Trojaola A, Sancho A, Götz R, Eiring P, Walz S, Jetani H, Gil-Pulido J, Da Via MC, Teufel E, Rhodes N, Haertle L, Arellano-Viera E, Tibes R, Rosenwald A, Rasche L, Hudecek M, Sauer M, Groll J, Einsele H, Kraus S, Kortüm MK.
    Commun Biol; 2021 Jun 25; 4(1):799. PubMed ID: 34172833
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Wu S, Edwards H, Wang D, Liu S, Qiao X, Carter J, Wang Y, Taub JW, Wang G, Ge Y.
    Cells; 2022 Sep 03; 11(17):. PubMed ID: 36078163
    [Abstract] [Full Text] [Related]

  • 11. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T.
    Leuk Res; 2021 Jan 03; 100():106490. PubMed ID: 33373830
    [Abstract] [Full Text] [Related]

  • 12. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
    Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, Heid D, Renders S, Göllner S, Vierbaum L, Besenbeck B, Herbst SA, Knoll M, Kolb C, Przybylla A, Weidenauer K, Ludwig AK, Fabre M, Gu M, Schlenk RF, Stölzel F, Bornhäuser M, Röllig C, Platzbecker U, Baldus C, Serve H, Sauer T, Raffel S, Pabst C, Vassiliou G, Vick B, Jeremias I, Trumpp A, Krijgsveld J, Müller-Tidow C, Dietrich S.
    Blood; 2022 Dec 15; 140(24):2594-2610. PubMed ID: 35857899
    [Abstract] [Full Text] [Related]

  • 13. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M, Shen C, Chen Y, Chen Z, Zhou K, Chen Y, Li W, Zeng C, Qing Y, Wu D, Xu C, Tang T, Che Y, Qin X, Xu Z, Wang K, Leung K, Sau L, Deng X, Hu J, Wu Y, Chen J.
    Cell Rep Med; 2024 Jul 16; 5(7):101645. PubMed ID: 39019012
    [Abstract] [Full Text] [Related]

  • 14. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
    Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, Wasmuth R, Beaver L, Cempre C, Skinner J, Cannon M, Govande M, Harrington B, Lehman A, Byrd JC, Lapalombella R, Blachly JS.
    J Hematol Oncol; 2020 Oct 19; 13(1):139. PubMed ID: 33076970
    [Abstract] [Full Text] [Related]

  • 15. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
    Lee JK, Chatterjee A, Scarpa M, Bailey CM, Niyongere S, Singh P, Mustafa Ali MK, Kapoor S, Wang Y, Silvestri G, Baer MR.
    Cancer Res Commun; 2024 Feb 16; 4(2):431-445. PubMed ID: 38284896
    [Abstract] [Full Text] [Related]

  • 16. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, Huszar D, Tron AE, Perrotti D, Baer MR.
    Clin Cancer Res; 2018 Jan 01; 24(1):234-247. PubMed ID: 29074603
    [Abstract] [Full Text] [Related]

  • 17. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H, Weng XQ, Sheng Y, Wu J, Xi HM, Cai X.
    BMC Cancer; 2022 Jul 09; 22(1):749. PubMed ID: 35810308
    [Abstract] [Full Text] [Related]

  • 18. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.
    Mol Cancer Ther; 2015 Oct 09; 14(10):2364-73. PubMed ID: 26206337
    [Abstract] [Full Text] [Related]

  • 19. Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib.
    Ha YN, Song S, Orlikova-Boyer B, Cerella C, Christov C, Kijjoa A, Diederich M.
    Mar Drugs; 2020 Jan 16; 18(1):. PubMed ID: 31963113
    [Abstract] [Full Text] [Related]

  • 20. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
    Satta T, Li L, Chalasani SL, Hu X, Nkwocha J, Sharma K, Kmieciak M, Rahmani M, Zhou L, Grant S.
    Clin Cancer Res; 2023 Apr 03; 29(7):1332-1343. PubMed ID: 36652560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.